TP53 and leukemia: Inhibition of neddylation by MLN4924 triggers anti-leukemia effects by inducing cell apoptosis, senescence, and autophagy, while activating the p53 signaling pathway, thus serving as a potential therapeutic strategy in AML treatment [54].